Arca
Skip to content
Tools
Tools

HDAC6: Protein deacetylase HDAC6

Deacetylates a wide range of non-histone substrates.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on HDAC6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Vorinostat

Phase 30

    Phase 21

    • Ricolinostat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      VorinostatApprovedMerck & Co. (MSD)Small moleculeInhibitorHistone deacetylase 6 inhibitor28
      RicolinostatPhase 2Bristol-Myers SquibbSmall moleculeInhibitorHistone deacetylase 6 inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabVorinostatPhase 2Not yet recruitingNew Approaches to Neuroblastoma Therapy ConsortiumDec 3, 2025
      An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.Sep 2, 2025
      Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.Sep 2, 2025
      Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) PopulationVorinostatPhase 2RecruitingSung Won ChoiMay 29, 2025
      A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]VorinostatEarly phase 1RecruitingUniversity of MinnesotaNov 18, 2024
      Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerVorinostatPhase 2RecruitingFred Hutchinson Cancer CenterNov 24, 2023
      TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIVorinostatPhase 1 / Phase 2RecruitingTanja Andrea GruberMay 8, 2023
      Venetoclax to Augment Epigenetic Modification and ChemotherapyVorinostatPhase 1RecruitingMedical College of WisconsinApr 7, 2022

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      X-linked dominant chondrodysplasia, Chassaing-Lacombe type
      0.59
      Plasma cell myeloma
      0.57
      Primary cutaneous T-cell non-Hodgkin lymphoma
      0.57
      Neoplasm
      0.57
      T-cell non-Hodgkin lymphoma
      0.52
      Peripheral T-cell lymphoma, not otherwise specified
      0.52
      Mature T-cell and NK-cell non-Hodgkin lymphoma
      0.50
      Neurodegenerative disease
      0.39

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      HDAC6

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1865, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9UBN7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.